Blade Air Mobility, Inc. (SRTA)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Strata Critical Medical, Inc. (SRTA) Upgraded to Buy: What Does It Mean for the Stock?
Strata Critical Medical, Inc. (SRTA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Does Strata Critical Medical, Inc. (SRTA) Have the Potential to Rally 47.28% as Wall Street Analysts Expect?
The mean of analysts' price targets for Strata Critical Medical, Inc. (SRTA) points to a 47.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Can Strata Critical Medical, Inc. (SRTA) Run Higher on Rising Earnings Estimates?
Strata Critical Medical, Inc. (SRTA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Wall Street Analysts Predict a 60% Upside in Strata Critical Medical, Inc. (SRTA): Here's What You Should Know
The consensus price target hints at a 60% upside potential for Strata Critical Medical, Inc. (SRTA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Strata Critical Medical, Inc. (SRTA) Q2 2026 Earnings Call Transcript
Strata Critical Medical, Inc. (SRTA) Q2 2026 Earnings Call Transcript
Strata Critical Medical, Inc. (SRTA) Surges 8.5%: Is This an Indication of Further Gains?
Strata Critical Medical, Inc. (SRTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Strata Critical Medical: Significant Upside Potential Backed By Robust EBITDA Growth
Strata Critical Medical is rated 'Buy' with a 12–24 month horizon, targeting 30–35% upside as valuation remains attractive despite a recent rally. SRTA's transformation into a pure-play medical logistics provider, robust FY25 results, and margin expansion underpin confidence in forward guidance. Industry tailwinds, regulatory catalysts, and an aggressive acquisition strategy position SRTA for sustained revenue and EBITDA growth, with FY26 guidance implying an 11.6% EBITDA margin.
Strata Critical Medical, Inc. (SRTA) Q4 2025 Earnings Call Transcript
Strata Critical Medical, Inc. (SRTA) Q4 2025 Earnings Call Transcript
